Mouwasat Medical Services Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Mouwasat Medical Services wird ein jährliches Gewinn- und Umsatzwachstum von 15.7% bzw. 12.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 16.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 24.5% betragen.
Wichtige Informationen
15.5%
Wachstumsrate der Gewinne
16.1%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 14.8% |
| Wachstumsrate der Einnahmen | 12.7% |
| Zukünftige Eigenkapitalrendite | 24.1% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 10 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Mouwasat Medical Services Company's (TADAWUL:4002) Popularity With Investors Is Clear
Apr 23
Here's Why We Think Mouwasat Medical Services (TADAWUL:4002) Might Deserve Your Attention Today
Mar 18Slowing Rates Of Return At Mouwasat Medical Services (TADAWUL:4002) Leave Little Room For Excitement
Jan 23Here's Why Mouwasat Medical Services (TADAWUL:4002) Has Caught The Eye Of Investors
Dec 17Mouwasat Medical Services (TADAWUL:4002) Has Some Way To Go To Become A Multi-Bagger
Oct 05Should You Be Adding Mouwasat Medical Services (TADAWUL:4002) To Your Watchlist Today?
Sep 17The Returns At Mouwasat Medical Services (TADAWUL:4002) Aren't Growing
Jul 03Is Now The Time To Put Mouwasat Medical Services (TADAWUL:4002) On Your Watchlist?
Jun 12Returns At Mouwasat Medical Services (TADAWUL:4002) Appear To Be Weighed Down
Feb 24Mouwasat Medical Services Company's (TADAWUL:4002) Intrinsic Value Is Potentially 25% Below Its Share Price
Jan 18Return Trends At Mouwasat Medical Services (TADAWUL:4002) Aren't Appealing
Nov 24Returns At Mouwasat Medical Services (TADAWUL:4002) Appear To Be Weighed Down
Aug 24A Look At The Fair Value Of Mouwasat Medical Services Company (TADAWUL:4002)
Jul 01Time To Worry? Analysts Just Downgraded Their Mouwasat Medical Services Company (TADAWUL:4002) Outlook
May 23Mouwasat Medical Services (TADAWUL:4002) Will Pay A Larger Dividend Than Last Year At ر.س2.75
Apr 29Mouwasat Medical Services (TADAWUL:4002) Is Increasing Its Dividend To ر.س2.75
Apr 15Investors Will Want Mouwasat Medical Services' (TADAWUL:4002) Growth In ROCE To Persist
Mar 17Calculating The Fair Value Of Mouwasat Medical Services Company (TADAWUL:4002)
Mar 02If You Like EPS Growth Then Check Out Mouwasat Medical Services (TADAWUL:4002) Before It's Too Late
Feb 15The Return Trends At Mouwasat Medical Services (TADAWUL:4002) Look Promising
Dec 06Do Mouwasat Medical Services's (TADAWUL:4002) Earnings Warrant Your Attention?
Nov 16Mouwasat Medical Services (TADAWUL:4002) Is Achieving High Returns On Its Capital
Aug 29Does Mouwasat Medical Services (TADAWUL:4002) Deserve A Spot On Your Watchlist?
Aug 12Is Mouwasat Medical Services Company (TADAWUL:4002) Expensive For A Reason? A Look At Its Intrinsic Value
Jun 29Mouwasat Medical Services' (TADAWUL:4002) Returns On Capital Are Heading Higher
May 26Does Mouwasat Medical Services (TADAWUL:4002) Deserve A Spot On Your Watchlist?
May 11Is It Worth Buying Mouwasat Medical Services Company (TADAWUL:4002) For Its 1.4% Dividend Yield?
Apr 13Estimating The Intrinsic Value Of Mouwasat Medical Services Company (TADAWUL:4002)
Mar 16Is Mouwasat Medical Services Company's (TADAWUL:4002) Latest Stock Performance Being Led By Its Strong Fundamentals?
Mar 02Is Mouwasat Medical Services (TADAWUL:4002) A Future Multi-bagger?
Feb 13Here's Why I Think Mouwasat Medical Services (TADAWUL:4002) Is An Interesting Stock
Feb 01
What Kind Of Shareholders Hold The Majority In Mouwasat Medical Services Company's (TADAWUL:4002) Shares?
Jan 17What Makes Mouwasat Medical Services Company (TADAWUL:4002) A Great Dividend Stock?
Jan 04Mouwasat Medical Services (TADAWUL:4002) Has Gifted Shareholders With A Fantastic 137% Total Return On Their Investment
Dec 21Estimating The Fair Value Of Mouwasat Medical Services Company (TADAWUL:4002)
Dec 08Mouwasat Medical Services Company's (TADAWUL:4002) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 24Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 4,143 | 1,057 | 1,049 | 1,229 | 7 |
| 12/31/2025 | 3,574 | 880 | 796 | 1,112 | 10 |
| 12/31/2024 | 3,045 | 756 | 689 | 968 | 6 |
| 3/31/2024 | 2,764 | 663 | 521 | 867 | N/A |
| 12/31/2023 | 2,706 | 658 | 527 | 814 | N/A |
| 9/30/2023 | 2,593 | 659 | 833 | 1,034 | N/A |
| 6/30/2023 | 2,501 | 625 | 779 | 970 | N/A |
| 3/31/2023 | 2,431 | 616 | 517 | 779 | N/A |
| 12/31/2022 | 2,334 | 599 | 409 | 707 | N/A |
| 9/30/2022 | 2,226 | 561 | 213 | 572 | N/A |
| 6/30/2022 | 2,208 | 581 | 162 | 542 | N/A |
| 3/31/2022 | 2,177 | 581 | 313 | 642 | N/A |
| 12/31/2021 | 2,144 | 578 | 353 | 683 | N/A |
| 9/30/2021 | 2,125 | 574 | 342 | 657 | N/A |
| 6/30/2021 | 2,143 | 593 | 368 | 643 | N/A |
| 3/31/2021 | 2,085 | 567 | 287 | 537 | N/A |
| 12/31/2020 | 2,045 | 528 | 247 | 481 | N/A |
| 9/30/2020 | 2,016 | 515 | 258 | 529 | N/A |
| 6/30/2020 | 1,911 | 447 | 238 | 520 | N/A |
| 3/31/2020 | 1,889 | 422 | 255 | 533 | N/A |
| 12/31/2019 | 1,857 | 421 | 371 | 635 | N/A |
| 9/30/2019 | 1,808 | 376 | 339 | 548 | N/A |
| 6/30/2019 | 1,769 | 364 | 301 | 548 | N/A |
| 3/31/2019 | 1,717 | 361 | 202 | 509 | N/A |
| 12/31/2018 | 1,677 | 360 | 74 | 386 | N/A |
| 9/30/2018 | 1,652 | 373 | -2 | 364 | N/A |
| 6/30/2018 | 1,608 | 369 | 110 | 446 | N/A |
| 3/31/2018 | 1,567 | 358 | 181 | 462 | N/A |
| 12/31/2017 | 1,507 | 337 | N/A | 452 | N/A |
| 9/30/2017 | 1,435 | 314 | N/A | 462 | N/A |
| 6/30/2017 | 1,356 | 286 | N/A | 414 | N/A |
| 3/31/2017 | 1,303 | 274 | N/A | 336 | N/A |
| 12/31/2016 | 1,243 | 257 | N/A | 306 | N/A |
| 9/30/2016 | 1,144 | 235 | N/A | 190 | N/A |
| 6/30/2016 | 1,095 | 229 | N/A | 130 | N/A |
| 3/31/2016 | 1,050 | 221 | N/A | 173 | N/A |
| 12/31/2015 | 1,000 | 209 | N/A | 207 | N/A |
| 9/30/2015 | 926 | 206 | N/A | 271 | N/A |
| 6/30/2015 | 925 | 235 | N/A | 306 | N/A |
| 3/31/2015 | 914 | 238 | N/A | 301 | N/A |
| 12/31/2014 | 904 | 240 | N/A | 286 | N/A |
| 9/30/2014 | 961 | 240 | N/A | 268 | N/A |
| 6/30/2014 | 942 | 212 | N/A | 267 | N/A |
| 3/31/2014 | 927 | 207 | N/A | 281 | N/A |
| 12/31/2013 | 902 | 201 | N/A | 271 | N/A |
| 9/30/2013 | 873 | 193 | N/A | 245 | N/A |
| 6/30/2013 | 848 | 185 | N/A | 209 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 4002Das prognostizierte Gewinnwachstum (15.7% pro Jahr) liegt über der Sparquote (14.3%).
Ertrag vs. Markt: 4002Die Erträge des Unternehmens (15.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (6.8% pro Jahr).
Hohe Wachstumserträge: 4002Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: 4002Die Einnahmen des Unternehmens (12.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (-0.3% pro Jahr).
Hohe Wachstumseinnahmen: 4002Die Einnahmen des Unternehmens (12.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 4002Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (24.5%)